Am. J. Respir. Crit. Care Med., Volume 162, Number 5, November 2000, 1819-1822

Lung Deposition of Inhaled Drugs Increases with Age

JACOB ANH ØJ, LARS THORSSON, and HANS BISGAARD

Department of Paediatrics, Rigshospitalet; Copenhagen University Hospital, Copenhagen, Denmark; and AstraZeneca R&D Lund; and Experimental Medicine, Lund, Sweden

Budesonide plasma concentrations after inhalation of a fixed dose of the drug from a pressurized metered dose inhaler (pMDI) with spacer (Nebuchamber) were compared in young children and adults: 26 patients with mild asthma comprising 8 children 2-3 yr, 8 children 4-6 yr, and 10 adults 20-41 yr. Budesonide 2 × 200 µg was given by pMDI via Nebuchamber with mouthpiece and noseclip. Children of 2-3 yr used a facemask. Plasma was collected regularly for 8 h after drug administration. Budesonide was measured by liquid chromatography plus tandem mass spectrometry. The dose to patient was estimated as the dose of budesonide delivered from the pMDI with adapter minus the amount of budesonide recovered from the spacer, facemask, or mouthpiece, mouth rinse, and facial skin. The systemic exposure was estimated from the plasma concentration and expressed as the area under the curve of plasma concentration versus time (AUC). Terminal half-life (T_1/2) was evaluated. Dose to patient, AUC, and T_1/2 were similar in the three age groups (p > 0.35). Nebuchamber delivers the same dose of budesonide to young children and adults. Yet the plasma concentration of budesonide was similar in young children and adults. Therefore, lung dose is increased with age. This suggests that from a safety perspective, the prescribed dose of budesonide inhaled from a pMDI with Nebuchamber spacer need not be adjusted for age or use of facemask. Children and adults can use the same nominal dose of budesonide via Nebuchamber as adults without an increased risk of systemic exposure.

This article has been cited by other articles:

				L. Loland and H. Bisgaard Feasibility of Repetitive Lung Function Measurements by Raised Volume Rapid Thoracoabdominal Compression During Methacholine Challenge in Young Infants Chest, January 1, 2008; 133(1): 115 - 122. [Abstract] [Full Text] [PDF]

				A. Becker, C. Lemiere, D. Berube, L.-P. Boulet, F. M. Ducharme, M. FitzGerald, T. Kovesi, and on behalf of The Asthma Guidelines Working Group o Summary of recommendations from the Canadian Asthma Consensus Guidelines, 2003 Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S3 - S11. [Full Text] [PDF]

				Inhalation devices Can. Med. Assoc. J., September 13, 2005; 173(6_suppl): S39 - S45. [Full Text] [PDF]

				W. K. Kraft, B. Steiger, D. Beussink, J. N. Quiring, N. Fitzgerald, H. E. Greenberg, and S. A. Waldman The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers J. Clin. Pharmacol., January 1, 2004; 44(1): 67 - 72. [Abstract] [Full Text] [PDF]

				L. Agertoft and S. Pedersen Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in Children Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 779 - 782. [Abstract] [Full Text] [PDF]

				G Russell Inhaled corticosteroids and adrenal insufficiency Arch. Dis. Child., December 1, 2002; 87(6): 455 - 456. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580. [Full Text] [PDF]

				M. J. TOBIN Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594. [Full Text] [PDF]

				S. PEDERSEN Do Inhaled Corticosteroids Inhibit Growth in Children? Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 521 - 535. [Full Text] [PDF]

				I. Amirav, M. T. Newhouse, H. Bisgaard, J. Anhoi, and L. Thorsson LUNG DEPOSITION OF INHALED DRUGS INCREASES WITH AGE? Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1279 - 1279. [Full Text]